Molecular Partners AG
SIX:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
SIX:MOLN
Watchlist
Price: 4.85 CHF 0.73% Market Closed
Market Cap: 178.8m CHF
Have any thoughts about
Molecular Partners AG?
Write Note

Molecular Partners AG
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Molecular Partners AG
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
Molecular Partners AG
SIX:MOLN
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
PP&E Gross
$16.1m
CAGR 3-Years
50%
CAGR 5-Years
61%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
PP&E Gross
CHf5.8m
CAGR 3-Years
-8%
CAGR 5-Years
1%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
PP&E Gross
$284.8m
CAGR 3-Years
0%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
PP&E Gross
CHf19.4m
CAGR 3-Years
73%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
PP&E Gross
CHf2.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Molecular Partners AG
Glance View

Market Cap
178.8m CHF
Industry
Biotechnology

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

MOLN Intrinsic Value
3.07 CHF
Overvaluation 37%
Intrinsic Value
Price

See Also

Back to Top